All In Biotech

Drug Trial Radar · NCT06083753

Study to Evaluate the Safety and Efficacy of PIPE-307 in Subjects With Relapsing-Remitting Multiple Sclerosis

A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Multicenter Study to Evaluate the Safety and Efficacy of Oral PIPE-307 as an Adjunctive Treatment in Subjects With Relapsing-Remitting Multiple Sclerosis

Last checked: Nov 19, 2026Latest source record: Sep 25, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 182 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

182

Actual

Start

Nov 6, 2023

Primary completion

Jul 14, 2025

Study completion Aug 4, 2025

Sponsor

Lead sponsor
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
Sponsor type
Industry
First posted
Oct 16, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 50 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a randomized, double-blind study of PIPE-307 or placebo in subjects with relapsing-remitting multiple sclerosis. Subjects will be randomized into 1 of 3 separate cohorts (1:1:1 randomization ratio, PIPE-307 Dose A:PIPE-307 Dose B: Placebo) for a total duration of approximately 30 weeks.

Conditions

  • Relapsing Remitting Multiple Sclerosis

Interventions

  • PIPE-307 Dose ADrug

    Subjects will receive daily oral doses of PIPE-307

  • PIPE-307 Dose BDrug

    Subjects will receive daily oral doses of PIPE-307

  • PlaceboDrug

    Subjects will receive daily oral matching dose of Placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Treatment-emergent adverse events (TEAE)Time frame: From baseline to week 26 (end of treatment period)
  2. Change in binocular 2.5% low contrast letter acuity (LCLA)Time frame: From baseline to week 26 (end-of-study)

Locations

21 sites in 1 country. Site status is shown where the registry gives one.

  • Xenosciences

    Phoenix, Arizona

  • Arizona Neuroscience Research, LLC

    Phoenix, Arizona

  • Alta Bates Summit Medical Center

    Berkeley, California

  • Colorado Springs Neurological Associates

    Colorado Springs, Colorado

  • MS and Neuromuscular Center of Excellence

    Clearwater, Florida

  • Aqualane Clinical Research

    Naples, Florida

  • Shepherd Center

    Atlanta, Georgia

  • University of Kansas Medical Center

    Kansas City, Kansas

  • Neurology Center of New England P.C.

    Foxborough, Massachusetts

  • Washington University School of Medicine

    St Louis, Missouri

  • University of New Mexico/Health Science Center/MIND Imaging Center/MS Specialty Clinic

    Albuquerque, New Mexico

  • Dent Neurologic Institute

    Amherst, New York

  • Neurological Associates of Long Island, P.C.

    Lake Success, New York

  • Oklahoma Research Foundation - MS Center of Excellence

    Oklahoma City, Oklahoma

  • Sibyl Wray Neurology PC

    Knoxville, Tennessee

  • University of Texas Health Science Center at Houston

    Houston, Texas

  • Clinical Trial Network

    Houston, Texas

  • Bhupesh Dihenia, MD, PA

    Lubbock, Texas

  • Virginia Mason Medical Center

    Seattle, Washington

  • UW Medicine MS Center

    Seattle, Washington

  • Multicare Neuroscience Center of Washington

    Tacoma, Washington

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.